logo
Plus   Neg
Share
Email

Geron : Clinical Trial Activities Impacted By COVID-19 Pandemic, Cuts Spending

Geron Corp. (GERN) said that its clinical trial activities are being impacted in countries where healthcare systems are severely affected by the COVID-19 pandemic.

Due to the circumstances, the company no longer expects to complete enrollment in the IMerge Phase 3 trial or to commence our proof of concept study in high risk MDS and AML by the end of 2020, as it had originally planned.

The company said it cannot predict the long-term effect on IMerge timelines until it has more visibility on the length of the COVID-19, crisis and its impact on its IMerge clinical trial activities.

The company said that, to actively conserve its financial resources during these uncertain times, it has implemented measures to manage its near-term cash burn, and expect its spending in 2020 will be lower than the $70 to $75 million it previously guided.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
RELATED NEWS
Follow RTT